Cannabics Pharmaceuticals Inc. announced that it has filed a Provisional Patent Application with the US Patent & Trademark Office (USPTO) entitled “Composition and Method for Treating Colon Cancer with Cannabinoids”.
The application specifically targets Colon Cancer and follows the Company’s preclinical development of a novel formulation containing various cannabinoids which have been shown to demonstrate anti-tumor properties in studies focused on gastrointestinal cancers.
The composition contains high concentrations of the cannabinoids in a proprietary formulation. Having demonstrated complex combinatorial anti-tumor effects and lacking psychoactive effects, the composition may enable patients to be treated with high dosages without intoxication.
The company plans to examine the clinical safety and efficacy of the novel formulation in clinical studies in Israel where regulation permits the clinical validation process through GMP certified cannabis-based products.